Wuhan YZY Biopharma Co. Ltd.

Wuhan YZY Biopharma Co. Ltd. YZY Biopharma is a biotech company whose vision is to develop new class of innovative medicines based on breakthrough discovery in molecular biology. The company was founded in July 0f 2010, and is located in Wuhan National Biological Industry Base – Wuhan Biolake. As our scientists continue to investigate molecular disease targets to impact a broad range of human cancer, the possibility of targeting these previously “undruggable” targets with Bi-specific antibodies, MicroRNAs, RNAi etc. is transformative for new drug discovery. Our strategy at YZY is to lead the translation of the science of cancer biology into a robust drug discovery capability and to build a significant product pipeline of innovative medicines that we commercialize alone or with our partners. Our long term goals are to provide physicians with novel antibodies and minimize toxic side effects. YZY Biopharma has 4,000 square meters of state-of-the-art R&D center, and plans to build a 25,000-square-meter manufacturing base to mass produce therapeutic antibody products. Besides, the company has a privilege of advanced biotechnology and a strong scientist team led by experienced experts in the area. YZY will constantly promote core competence and continuously search for excellent, in order to have an impact on the world by discovering innovative new medicine. Our Research Pipeline • Tumor Therapeutic Antibodies • Cancer Stem Cells (CSCs) Our Technology Platform • Flow Cytometry Core Facility • Microarrays • Pre-clinical Drug Screening • Bio-therapy of Tumor 武汉友芝友生物制药有限公司成立于2010年7月，注册地位于武汉市东湖开发区高新大道666号，公司是一家专门从事生物医药自主创新研发的高新技术企业，公司已在武汉光谷生物城创新基地建立4000平米研发实验楼，并在光谷生物城产业基地投资建设““肿瘤治疗双抗体生产基地”。 公司致力于建立统一规范化的与恶性肿瘤相关的临床及前临床生物标本库、生物信息库，开发研制创新的肿瘤分子生物标记物。公司还将建立独特的抗体资源平台，构建大容量的人类抗肿瘤抗体及抗肿瘤干细胞抗体库，针对重要的靶点分子，高通量筛选制备极具开发治疗价值的功能性抗体，推动生物制药领域的研究，促进个性化医疗服务水平。 研发方向： • 肿瘤免疫双靶向抗体药物 (YZY-BiBody™) • 肿瘤干细胞 研发平台： • 流式细胞技术 • 微阵列基因芯片分析 • 肿瘤药物前临床筛选 • 肿瘤细胞治疗